Sgd Pharma
Sgd Pharma, headquartered in France, is a leading player in the pharmaceutical packaging industry, specialising in the design and manufacture of glass primary packaging solutions. Founded in 2002, the company has established a strong presence across Europe, Asia, and the Americas, catering to the diverse needs of the pharmaceutical and biotechnology sectors. With a commitment to quality and innovation, Sgd Pharma offers a comprehensive range of products, including vials, ampoules, and syringes, all designed to meet stringent regulatory standards. Their unique approach combines advanced manufacturing techniques with a focus on sustainability, positioning them as a trusted partner for global pharmaceutical companies. Notably, Sgd Pharma has achieved significant milestones in product development and market expansion, solidifying its reputation as a key player in the industry.
DitchCarbon Score
How does Sgd Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Rubber and Plastic Products industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sgd Pharma's score of 41 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Sgd Pharma's reported carbon emissions
In 2023, SGD Pharma reported total greenhouse gas emissions of approximately 203,584,000 kg CO2e for Scope 1, 199,732,000 kg CO2e for Scope 2, and 10,000,000 kg CO2e for Scope 3. This reflects a commitment to reducing absolute Scope 1 and 2 emissions by 42% by 2030 from a 2022 baseline, alongside a 25% reduction target for Scope 3 emissions within the same timeframe. The company's emissions data shows a trend of fluctuating emissions over recent years, with Scope 1 and 2 emissions peaking at about 218,003,000 kg CO2e in 2020 before decreasing to the current levels. SGD Pharma's commitment to the Science Based Targets initiative (SBTi) underscores its dedication to aligning with climate science and industry standards. Overall, SGD Pharma is actively working towards significant emissions reductions, demonstrating a proactive approach to climate commitments in the containers and packaging sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Get Started| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 216,495,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 78,007,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 1,899,000 | - | - | 0,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sgd Pharma is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
